SEC Form 4 · accession 0001209191-17-006402
ANAPTYSBIO, INC · ANAB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hamza Suria
Officer — President, CEO · Director
Period of report
Jan 31, 2017
Accepted (ET)
Jan 31, 2017 · 4:44 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001370053
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 31, 2017 | C | 4,998 | $0.00 | A | 4,998 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series C PreferredF1 | $0.00 | Jan 31, 2017 | C | 2,197 | D | — | — | Common Stock | 2,197 | 0 | D |
| Series C-1 PreferredF1 | $0.00 | Jan 31, 2017 | C | 781 | D | — | — | Common Stock | 781 | 0 | D |
| Series D PreferredF1 | $0.00 | Jan 31, 2017 | C | 2,020 | D | — | — | Common Stock | 2,020 | 0 | D |
Explanation of responses
- F1In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.